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Background: The incidence and correlates of stent thrombosis (ST) in the very late
follow-up (FU) post drug-eluting stent (DES) implantation is still not fully understood.
We report the very late FU (up to 10 years) of a large cohort of patients undergoing DES
implantation in daily clinical practice.
Methods: The DESIRE (Drug-Eluting Stent in the Real World) Registry is a prospective,
non-randomized clinical trial evaluating the long-term clinical FU of pts undergoing
elective or urgent percutaneous coronary intervention (PCI) with DES as the default
strategy in a single center. From 05/02 to 05/12, 4,229 pts (6,518 lesions) were treated
with 7,000 DES. Clinical FU was performed at 1, 6 and 12 months, and annually up to
10 years (FU in 97%) median  4.9 years). ST was defined according to the Academic
Research Consortium criteria.
Results: Overall, mean age was 64.3 years, 31% had dibetes, 30% current smoking, 23%
previous myocardial infarction (MI), 9.2% renal insufficiency, given that the majority of
patients (50%) presented with acute coronary syndrome. The majority of lesions were
highly complex (64% type B2C), and a mean of 1.6 stents per patient were implanted with
angiographic success achieved in99% os lesions. Regarding the DES, most of patients
were treated with first-generation DES (83%) with the remaining receiving second-
generation DES. The cumulative incidence of ST up 10 years was 2.3% (n97), including
definite, probable and possible ST in 52%, 2% and 46%, respectively. ST was classified
as acute (1%), subacute 13%, late 27%, and very late 59%. At 10 years, 95.9% of pts were
ST-free according ot the Kaplan-Meier method. In the multivariate model, the following
significant predictors of ST were identified: clinical presentation of acute MI (HR 2.52,
p0.001), current smoking (HR 1.64, p0.003), 1 DES implanted (HR 2.10,
p0.001), severe lesion calcification (HR 5.03, p0.007), and in-stent residual stenosis
(HR 1.04 per % unit increase, p0.001).
Conclusions: In this subanalysis, the cumulative incidence of ST up to 10 years was
relatively low, given that this phenomenon was significantly associated with recent MI,
smoking, multiple DES implanted, lesion complexity and residual stenosis.
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Background: Small studies in the early stent era demonstrated lower event-free survival
with BMS in calcified lesions. While DES have substantially improved clinical and
angiographic outcomes in various lesion subsets, surprisingly little is known about the
impact of moderate/severe coronary calcification on outcomes after PCI with DES.
Methods: 11,651 pts treated with DES were pooled from 14 randomized trials in which
qualitative and quantitative coronary angiography was performed by an independent core
laboratory. Patients were divided into 2 groups according to whether PCI lesions were vs.
were not moderately/severely calcified. Major outcomes were assessed at 1 year.
Results: Among the total cohort, 2,418 pts (20.8%) had moderately/severely calcified
PCI lesions. The presence of moderate/severe PCI lesion calcification was associated with
older age, active smoking, previous PCI or CABG, unstable angina at presentation, longer
lesions, and greater number of stents implanted. At 1 year the unadjusted rates of death,
MI and ischemic TLR or TVR were significantly increased in the group with moderate/
severe calcification (Table). By multivariate analysis, the presence of moderate/severe
PCI lesion calcification was a strong independent predictor of ischemic TLR (HR
[95%CI]1.42 [1.13, 1.80], p0.03) and composite MACE (death, MI or TLR; HR
[95%CI]1.35 [1.14,1.60], p0.0004).
Table. One-year rates of major events stratified by presence of moderate/




Calcification HR [95% CI] P Value
Death 1.9% (45) 1.2% (107) 1.61 [1.14,2.28] 0.006
Cardiac 1.0% (23) 0.6% (55) 1.60 [0.98,2.61] 0.055
Non-cardiac 0.9% (22) 0.6% (52) 1.62 [0.98,2.67] 0.055
MI 4.1% (98) 2.7% (248) 1.52 [1.20,1.92] 0.0004
Q-Wave 0.7% (16) 0.4% (36) 1.70 [0.94,3.06] 0.07
Non Q-Wave 3.5% (83) 2.3% (214) 1.49 [1.16,1.92] 0.002
Ischemic TLR 5.2% (122) 3.9% (356) 1.32 [1.07,1.62] 0.008
Ischemic TVR 7.1% (168) 5.9% (533) 1.21 [1.02,1.44] 0.03
Stent thrombosis
ARC definite 0.8% (19) 0.5% (47) 1.55 [0.91,2.64] 0.1
ARC probable 0.1% (3) 0.2% (19) 0.60 [0.18,2.04] 0.41
ARC definite/
probable
0.9% (22) 0.7% (63) 1.34 [0.82,2.17] 0.24
Death/MI 5.7% (138) 3.8% (343) 1.55 [1.27,1.89] 0.0001
Cardiac death/MI 4.9% (118) 3.2% (292) 1.56 [1.26,1.93] 0.0001
MACE (death/MI/
TLR)
10.4% (249) 7.6% (690) 1.40 [1.21,1.62] 0.0001
Value estimates are % (n) determined by Kaplan-Meier method.
CIconfidence interval; MImyocardial infarction; TLRtarget lesion
revascularization; TVRtarget vessel revascularization; ARCAcademic
Research Consortium.
Conclusions: In the DES era, PCI of moderate/severely calcified lesions is independently
predictive of increased rates of ischemic TLR and MACE at 1 year. Novel approaches are
needed to improve outcomes after PCI in these complex lesions.
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Background: In this study, contributing factors associated with in vivo coronary
drug-eluting stent (DES) fracture occurrence were identified from the literature and
translated into the setup of an aggressive fatigue-to-fracture (FtF) test method. Based on
the literature review findings, the FtF test method was designed to incorporate overlapping
stent deployment, aggressive stent bending, and Sirolimus Eluting Stent (SES) type as a
baseline, and was used to compare the fatigue resistance of multiple second-generation
DES designs to that of a baseline first-generation DES.
Methods: Fifty-six (56) case reports and 30 large population pooled studies were
analyzed to define appropriate factors to be incorporated in the FtF test method. Under
combined and exacerbated cyclic loading, the average number of cycles to fracture for
each tested DES was tabulated. Tested stent designs spanned across multiple commer-
cially used metal alloys, strut thickness values (81 m to 140 m), various numbers
of connectors between stent rings (2 – 6), and various stent link designs (peak-to-peak,
mid-strut to mid-strut, and peak-to-valley). The test setup was also simulated using finite
element analysis (FEA) to clarify which DES design features contribute to fatigue resistance.
Results: For the baseline DES, failure modes induced in testing were consistent with in
vivo fractures described in literature, and associated stent design features were identified
based on the failure modes observed. Compared to the baseline stent design, uniform but
short links were beneficial (3X life) while long and uniform flexible links were of further
benefit when combined with cobalt chromium material type (7X life).
Conclusions: This study demonstrated how contributing factors from clinical experience
can be identified and translated into the setup of FtF test methods and computational
models. Based on the results presented, key stent design features contributing to improved
fatigue resistance were identified as thin strut thickness, long and uniform flexible links,
and the use of the cobalt-chromium alloy, which exhibits a higher fatigue resistance when
compared to alloys such as stainless steel.
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